Analytical Data
-
Gene name
ATF7IP2
- Application
-
Alternative Names
ATF7-interacting protein 2;MBD1-containing chromatin-associated factor 2
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5U623
-
Expression Region
1–682aa
-
Molecular Weight
81.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ATF7IP2, a member of the ATF/CREB family of transcription factors, has garnered significant interest in recent years due to its potential roles in various cellular processes, including metabolism, stress response, and neurodevelopment. This protein is known to interact with other key factors in the regulatory network, influencing gene expression and cellular signaling pathways. Understanding the structure and function of ATF7IP2 is crucial, as its dysregulation has been implicated in several diseases, such as cancer and neurological disorders. Researchers have focused on the recombinant expression of ATF7IP2 to study its biochemical properties, functional domains, and interaction partners. The development of recombinant ATF7IP2 provides a platform for elucidating its biological roles and therapeutic potential. By characterizing this protein through methods such as X-ray crystallography and NMR spectroscopy, scientists aim to identify small molecules or peptides that could modulate its activity, offering new avenues for drug discovery. Overall, the exploration of ATF7IP2 as a recombinant protein is a promising frontier in molecular biology, with implications for understanding disease mechanisms and developing targeted therapies.
